Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Santoro

Showing results (51-60 of 201) with videos related to

Pageof 21
Sort By:
Nucleic Acids Research|December 15, 2007
siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinomaHenri de Martimprey, Jean-Remi Bertrand, Alfredo Fusco, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|January 3, 2018
Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patientsMassimo Santoro, Luana Fontana, Francesca Maiorca, et al.
Neurotoxicity Research|October 31, 2014
Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's diseaseMonica Colamartino, Massimo Santoro, Guglielmo Duranti, et al.
Oncogene|June 9, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsFrancesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutantsTeresa Guida, Suresh Anaganti, Livia Provitera, et al.
Experimental and Molecular Pathology|August 6, 2010
Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2)Massimo Santoro, Anna Modoni, Marcella Masciullo, et al.
Molecular Endocrinology (Baltimore, Md.)|August 6, 2011
A TSH-CREB1-microRNA loop is required for thyroid cell growthVincenza Leone, Daniela D'Angelo, Angelo Ferraro, et al.
Cancer Research|January 25, 2012
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cellsValentina De Falco, Anna Tamburrino, Simona Ventre, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutationsGiuliana Salvatore, Gennaro Chiappetta, Yuri E Nikiforov, et al.
Journal of the Neurological Sciences|July 19, 2017
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patientsMassimo Santoro, Massimiliano Mirabella, Chiara De Fino, et al.
Pageof 21

Showing results (51-60 of 201) with videos related to

Sort By:
Pageof 21
Nucleic Acids Research|December 15, 2007
siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinomaHenri de Martimprey, Jean-Remi Bertrand, Alfredo Fusco, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|January 3, 2018
Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patientsMassimo Santoro, Luana Fontana, Francesca Maiorca, et al.
Neurotoxicity Research|October 31, 2014
Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's diseaseMonica Colamartino, Massimo Santoro, Guglielmo Duranti, et al.
Oncogene|June 9, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsFrancesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutantsTeresa Guida, Suresh Anaganti, Livia Provitera, et al.
Experimental and Molecular Pathology|August 6, 2010
Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2)Massimo Santoro, Anna Modoni, Marcella Masciullo, et al.
Molecular Endocrinology (Baltimore, Md.)|August 6, 2011
A TSH-CREB1-microRNA loop is required for thyroid cell growthVincenza Leone, Daniela D'Angelo, Angelo Ferraro, et al.
Cancer Research|January 25, 2012
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cellsValentina De Falco, Anna Tamburrino, Simona Ventre, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutationsGiuliana Salvatore, Gennaro Chiappetta, Yuri E Nikiforov, et al.
Journal of the Neurological Sciences|July 19, 2017
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patientsMassimo Santoro, Massimiliano Mirabella, Chiara De Fino, et al.
Pageof 21